News topic
Research News & Updates
New study readouts, preclinical results, and mechanism-of-action research relevant to peptide therapy.
6 articles in this topic
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
The SURMOUNT-5 trial settled the debate: tirzepatide produces 47% more weight loss than semaglutide. But the full picture is more nuanced than the headline.
GLP-1 Drugs and Cancer Risk: What the Research Actually Shows
The thyroid cancer boxed warning. The cancer-protective speculation. A 50-trial meta-analysis. Here is what the evidence actually says about GLP-1 medications and cancer risk.
BPC-157 Human Clinical Data: Where We Stand in 2026
With the FDA reclassification restoring compounding access, BPC-157 is back in focus. Here is an honest assessment of where the human evidence stands.
GLP-1 Drugs and Reduced Alcohol Consumption: An Unexpected Effect
Patients on Ozempic and Wegovy increasingly report reduced desire to drink alcohol. The neuroscience behind this effect is becoming clearer — and clinical trials are underway.
What Happens When You Stop Taking Ozempic or Mounjaro? New 2026 Research
A major Cleveland Clinic study of nearly 8,000 patients found that stopping GLP-1 drugs does not lead to the dramatic weight regain many fear. Average regain was just 0.5% at one year. Here is what the research actually shows.
Survodutide: The Dual GLP-1/Glucagon Agonist Targeting Liver Disease and Obesity
Survodutide combines GLP-1 and glucagon receptor agonism to target both obesity and metabolic liver disease — a differentiated approach that could reshape MASH treatment.